Novartis Heart Disease Drug Pelacarsen Fails Clinical Trial Milestone

Novartis announced that its experimental cardiovascular medication, pelacarsen, did not meet its primary efficacy endpoint in recent clinical testing. The failure has surprised many cardiologists and may impact future research into targeted lipid-lowering therapies.

4 Sept, 22:44 — 4 Sept, 22:44

Post Share

Sources

Showing 1 of 2 sources

NYTMostly Factual3h ago

Another Heart Drug Fails, Shocking Cardiologists

Doctors were hopeful the drug, which was being tested in a large clinical trial by Novartis, was going to be a powerful new tool to fight heart disease.

By Gina Kolata

Read full article →

Coverage Timeline

First report: wsj · 4 Sept, 21:46|Full coverage: 2 · 58m|Window: 58m

Left-leaningCenterRight-leaning

wsj4 Sept, 21:46First to report

Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint - WSJ

NYT4 Sept, 22:44Latest update

Novartis Heart Disease Drug Pelacarsen Fails Clinical Trial Milestone

Sources

Another Heart Drug Fails, Shocking Cardiologists

Coverage Timeline

Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint - WSJ

Another Heart Drug Fails, Shocking Cardiologists

Related Stories

Pennsylvania Infant Confirmed Dead From Measles

Salmonella Outbreak Linked to Pumpkin Seeds Infects Over 80 in France

European Countries Report Rising West Nile Virus Cases and Deaths

Patient Survives Nine Months After Receiving Pig Kidney Transplant